^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
liraltagene autoleucel (lira-cel)
i
Other names: lira-cel, Ovarian cancer CAR-T therapy, Follicle Stimulating Hormone Receptor T Cells
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Anixa Biosci, Moffitt Cancer Center
Drug class:
FSHR-targeted CAR-T immunotherapy
Related drugs:
6ms
MCC-21113: Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer (clinicaltrials.gov)
P1, N=10, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial primary completion date: Jul 2025 --> Jul 2026
Trial primary completion date
|
PD-L1 (Programmed death ligand 1) • BRCA (Breast cancer early onset)
|
BRCA mutation
|
liraltagene autoleucel (lira-cel)
9ms
MCC-21113: Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer (clinicaltrials.gov)
P1, N=10, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Active, not recruiting --> Recruiting
Enrollment open
|
PD-L1 (Programmed death ligand 1) • BRCA (Breast cancer early onset)
|
BRCA mutation
|
liraltagene autoleucel (lira-cel)
12ms
MCC-21113: Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer (clinicaltrials.gov)
P1, N=10, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | N=48 --> 10 | Recruiting --> Active, not recruiting
Enrollment closed • Enrollment change
|
PD-L1 (Programmed death ligand 1) • BRCA (Breast cancer early onset)
|
BRCA mutation
|
liraltagene autoleucel (lira-cel)
over1year
Transgelin 2 guards T cell lipid metabolism and antitumour function. (PubMed, Nature)
Accordingly, chimeric antigen receptor T cells overexpressing TAGLN2 bypassed the detrimental effects of tumour-induced ER stress and demonstrated therapeutic efficacy in mice with metastatic ovarian cancer. Our study establishes the role of cytoskeletal TAGLN2 in T cell lipid metabolism and highlights the potential to enhance cellular immunotherapy in solid malignancies by preserving the TAGLN2-FABP5 axis.
Journal • IO biomarker
|
ER (Estrogen receptor) • CD8 (cluster of differentiation 8) • FABP5 (Fatty Acid Binding Protein 5)
|
CD8 expression • TAGLN expression
|
liraltagene autoleucel (lira-cel)
over1year
EVEREST-2: a seamless phase 1/2 study of A2B694, a logic-gated Tmod CAR T-cell therapy, in patients with mesothelin-expressing solid tumors with human leukocyte antigen-A*02 loss of heterozygosity (SITC 2024)
a May occur at any point in disease course. CRC, colorectal cancer; D, day; MESO, mesothelioma; NSCLC, non-small cell lung cancer; OVCA, ovarian cancer; PANC, pancreatic cancer; PCLD, preconditioning lymphodepletionDownload figure Open in new tab Download powerpoint Abstract 627 Figure 3 EVEREST-2 phase 1 dose escalation study design
CAR T-Cell Therapy • P1/2 data • Clinical • IO biomarker
|
HLA-A (Major Histocompatibility Complex, Class I, A) • MSLN (Mesothelin)
|
MSLN expression • HLA-A*02
|
Tempus HLA-LOH assay
|
liraltagene autoleucel (lira-cel)
almost2years
Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer (clinicaltrials.gov)
P1, N=48, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial primary completion date: Mar 2024 --> Mar 2025
Trial primary completion date
|
PD-L1 (Programmed death ligand 1) • BRCA (Breast cancer early onset)
|
BRCA mutation
|
liraltagene autoleucel (lira-cel)
almost2years
CAR-T Cell Therapy in Ovarian Cancer: Where Are We Now? (PubMed, Diagnostics (Basel))
Ongoing challenges include cytokine-associated and "on-target, off-tumor" toxicities, while most common adverse events include cytokine release syndrome, hemophagocytic lymphohistiocytosis/macrophage activation-like syndrome (HLH/MAS), and neurotoxicity. In the present review, we summarize the current status of CAR-T therapy in ovarian cancer and discuss future directions.
Review • Journal • CAR T-Cell Therapy
|
HER-2 (Human epidermal growth factor receptor 2) • MSLN (Mesothelin) • CD276 (CD276 Molecule)
|
liraltagene autoleucel (lira-cel)
almost2years
CAR T-Cell Therapy • P1/2 data • Clinical • IO biomarker
|
HLA-A (Major Histocompatibility Complex, Class I, A) • MSLN (Mesothelin)
|
Tempus HLA-LOH assay
|
liraltagene autoleucel (lira-cel)
over3years
A Phase1/1b Dose Escalation/Dose Expansion Study of Prgn-3007 Ultracar-T Cells in Patients with Advanced Hematologic and Solid Tumor Malignancies (ASH 2022)
Study subjects undergo leukapheresis followed by lymphodepletion with either fludarabine 30mg/m2 and cyclophosphamide 500mg/m2 for 3 days (Arm 1) or 60 mg/kg cyclophosphamide for 2 days (Arm 2). All subjects will be followed for adverse events, CAR-T-related toxicities, disease response and PRGN-3007 cell expansion and persistence. In addition, the mechanisms of safety and effectiveness of PRGN-3007 cells will be evaluated with correlative assays of specific immune response pathways.
Clinical • P1 data • CAR T-Cell Therapy • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CCND1 (Cyclin D1) • ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1) • IL15 (Interleukin 15)
|
PD-1 expression • ROR1 expression • CCND1 overexpression
|
cyclophosphamide • fludarabine IV • PRGN-3005 • PRGN-3007 • liraltagene autoleucel (lira-cel)
almost4years
Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer (clinicaltrials.gov)
P1, N=48, Recruiting, H. Lee Moffitt Cancer Center and Research Institute
New P1 trial
|
PD-L1 (Programmed death ligand 1) • BRCA (Breast cancer early onset)
|
BRCA mutation
|
liraltagene autoleucel (lira-cel)
Share via
